A critical issue for cancer treatment is control of metastatic or disseminated tumors. Although immune gene therapy has been considered as a possible strategy for treatment of such tumors, successful results have not yet been obtained. To evoke antitumor immunity more efficiently, macrophage inflammatory protein -1 (MIP-1 ) was used for gene therapy of colon cancer in mice. Injection of hemagglutinating virus of Japan ( HVJ ) cationic liposomes -MIP -1 into subcutaneous tumor masses resulted in local expression of MIP -1 and local accumulation of CD4 + T lymphocytes. Few studies of cancer gene therapies have targeted peritoneal dissemination. In a mouse model of peritoneal dissemination of colon tumor, we used a luciferase -based assay to demonstrate that HVJ cationic liposomes had high tumor specificity and were effective vectors for transfer of genes in peritoneal dissemination. When mice were treated by intraperitoneal injection of HVJ cationic liposomes containing the MIP -1 gene, the survival periods of the MIP -1 -treated mice were significantly longer than those of control mice. Therefore, this HVJ cationic liposome strategy may serve as a powerful tool against peritoneal disseminated cancer. Cancer Gene Therapy ( 2001 ) Recent advances in immunological research have clarified the roles of chemokines in the immune system. Chemokines are small chemotactic cytokines that together with their receptors, orchestrate the distribution immune system effector cells. Several chemokines, including MIP -1, RANTES, MIP -3, and lymphotactin, have been transduced into tumors and have resulted in antitumor immunity.
G ene therapy has been proposed for the treatment of intractable human diseases. As of March 2000, more than 400 clinical protocols involving gene therapy had been undertaken in the United States, and approximately 70% of these were for cancer (http:// www.wiley.co.uk / genetherapy ).
Therapies based on cytokine genes have been tested. 1 Genes for various cytokines, including interleukin (IL )-1, -2, -4, -12, interferons, and GM -CSF have been transfected with retroviral vectors ex vivo into tumor /normal cells and evaluated as vaccines. These studies showed significant prevention of tumors and control of tumor progression in murine model systems. To date, however, clinical phase I and II studies have not yielded significant therapeutic results. Immune gene therapy is not specific, and it enhances a variety of immunological activities, not just those against cancer. Costimulatory factors and tumor-associated antigens have been identified and used to establish tumor-specific vaccines. 2 However, cancer cells frequently induce T-cell anergy to favor growth in the host. Therefore, genetic immunotherapy alone is too weak to prevent tumor progression. 3, 4 Recent advances in immunological research have clarified the roles of chemokines in the immune system. Chemokines are small chemotactic cytokines that together with their receptors, orchestrate the distribution immune system effector cells. Several chemokines, including MIP -1, RANTES, MIP -3, and lymphotactin, have been transduced into tumors and have resulted in antitumor immunity. 5 -10 However, no studies of cancer gene therapy with macrophage inflammatory protein -1 ( MIP -1 ) gene have been performed. MIP -1 is an 8-kDa member of the CC chemokine subfamily, which comprises molecules that are chemoattractants and activators of monocytes, macrophages, and T cells. 11 -15 In comparison to MIP -1, MIP-1 preferentially attracts CD4 + T lymphocytes. 14 CD4 + T lymphocytes can be classified into two subtypes: 16 Th1 lymphocytes secrete interferon gamma and IL -12; and Th2 lymphocytes secrete IL-4 and IL -5.
Judging from the fact that IL -12, a Th1 -activating cytokine, shows antitumor immunity, Th1 -dominant immunity is superior to Th2 immunity in the induction of antitumor immunity. 17 However, Th2 cytokines such as IL -4, IL-6, and IL -10 are also effective for tumor immunotherapy. 18 Although it is not clearly demonstrated whether CD4 + T helper cells are Th1 or Th2 type, these data indicate that CD4 + T helper cells may play an important role in antitumor immunity.
To improve the effectiveness of cancer gene therapy, gene delivery must be targeted preferentially cancer cells. The hemagglutinating virus of Japan ( HVJ ) -liposome gene transfer method enables delivery of nucleic acids or proteins directly and efficiently into host cells in vivo by means of the virus' cell fusion machinery. 19 We have developed many types of liposomes with the HVJ envelope and found that HVJ anionic liposomes were effective for transfer of genes to solid organs such as liver and muscle, whereas HVJ cationic liposomes were preferable for gene transfer to surface areas of organs such as bronchial epithelium and biliary epithelium. 20 -22 Cationic liposomes appeared to be more effective for cancer gene therapy than the anionic type. We also evaluated gene -transfer efficiency of anionic and cationic HVJ liposomes in peritoneally disseminated cancers. Peritoneal dissemination remains a major clinical problem as neither surgery nor chemotherapy can eradicate these tumors. In the present study, we report the effectiveness of MIP -1 gene therapy mediated by HVJ cationic liposomes against peritoneal dissemination of colon cancer.
MATERIALS AND METHODS

Plasmids
pc -Luc was constructed by subcloning the BamHI -XhoI fragment of the pGEM -luci vector ( Invitrogen, Madison, WI ), which contains the firefly luciferase gene, into the BamHI -XhoI site of a plasmid containing the CMV promoter, the first intron of the human growth hormone gene, and the SV40 early polyadenylation site. PORF and pORFmMIP-1 were purchased from Invivogen ( San Diego, CA ). pORF contains the hEF1/ HTLV-1 hybrid promoter.
Cells and cell culture
CT26 is an undifferentiated colon adenocarcinoma cell line derived from intrarectal injection of N -nitroso -N -methylurethane into a BALB /c mouse 23 and was kindly donated by MedGene (Osaka, Japan ). Cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, penicillin (50 U /mL ), and streptomycin ( 50 g /mL ). Cells were grown and incubated at 378C in 5% CO 2 -95% O 2 atmosphere.
Preparation of HVJ cationic liposome vector
Cholesterol (Chol), egg yolk phosphatidylcholine ( ePC ), egg yolk sphingomyelin (eSph ), dioleoylphosphatidylethanolamine ( DOPE ), and DCcholesterol ( DC -Chol ) were purchased from Sigma (St. Louis, MO ). Each lipid was dissolved in chloroform at a concentration of 30 mM. For the preparation of HVJ cationic liposomes, ePC, eSph, DOPE, Chol, and DC -Chol were mixed at a molar ratio of 16.7:16.7:16.7:40:10. 22 Five hundred microliters of the lipid mixture was transferred to a glass tube and dried to a thin lipid film by evaporation. Plasmid DNA (200 g) was mixed with 10 mg dried lipid. Liposomes containing plasmid DNA were prepared by vigorous vortexing followed by extrusion through filters ( pore sizes 0.45 and 0.20 m ). The liposome suspension was mixed with UV-inactivated HVJ suspension (15,000 hemagglutinating units, HAU ) and incubated on ice for 10 minutes, then for 1 hour at 378C. The HVJ liposome complexes were then separated from free HVJ by sucrose-density gradient centrifugation at 62,800Âg at 48C for 1.5 hours in a swinging -bucket rotor. HVJ cationic liposomes were collected into a sterilized tube.
Preparation of HVJ anionic liposome vector
Plasmid DNA was resuspended in 10 mM Tris -HCl, pH 8.0, 0.1 mM EDTA. DNA -HVJ anionic liposomes were prepared as described. 22 Briefly, 200 g plasmid DNA in 200 l of TE ( 10mM Tris -Cl pH8.0, 1mM EDTA ) was added to a tube containing dried lipid, shaken vigorously, and sonicated to form liposomes. Purified HVJ was inactivated by UV irradiation before use. One milliliter of HVJ solution was combined with the liposomes, and incubated on ice for 10 minutes followed by incubation for 1 hour at 378C. HVJ liposome complexes were then separated from free HVJ by sucrose-density gradient centrifugation at 62,800Âg at 48C for 2 hours in a swinging -bucket rotor. HVJ anionic liposomes were collected into a sterilized tube.
Immunohistochemical analysis
Colon tumor masses were generated by subcutaneous injection of 100 l CT26 suspension ( 1Â10 6 /100 l) into the backs of 8 -week -old BALB /c mice. BALB /c mice were purchased from Japan Animal Company (Osaka, Japan ). When tumor masses reached approximately 10 mm in diameter, 100 l of HVJ cationic liposome suspension containing pORF -mMIP -1 or pORF was injected. To demonstrate expression of the MIP -1 on day 1 after transfer of pORF -mMIP-1 or pORF to the colon tumor masses, the masses were resected and fixed with 3.7% paraformaldehyde. Frozen sections (10 m ) were then prepared and subjected to immunostaining with goat antimouse MIP -1 IgG polyclonal antibody ( primary antibody ) and fluorescein isothiocyanate (FITC ) -conjugated donkey anti -goat IgG secondary antibody (both from Santa Cruz Biotechnology, Santa Cruz, CA ). To demonstrate the accumulation of lymphocytes, the masses were resected on day 7 after transfer of pORF -mMIP -1 or pORF and fixed in paraformaldehyde. Tissues were then sectioned and submerged in the same fixative. Tissues were embedded in paraffin, and 4 m sections were placed on glass slides. For immunohistochemical studies, tissue sections were deparaffinized. After being blocked, the sections were subjected to immunostaining with rat antimouse CD4 (L3T4 ) or CD8 ( Ly -2 ) primary antibody ( both from PharMingen, San Diego, CA ) and peroxidaseconjugated goat anti -rat IgG secondary antibody (ICN Phamaceuticals, Aurora, OH ), then a histofine SAB -PO( M) kit (Nichirei, Tokyo, Japan ).
Luciferase assay
Eight-week -old male BALB /c mice used for the luciferase assay were treated in a humane fashion in accord with the guidelines of the Animal Committee of Osaka University. First, 5Â10 7 CT26 cells were injected intraperitoneally. To evaluate tumor specificity of HVJ cationic liposomes, HVJ cationic liposomes or HVJ anionic liposomes containing pcLuc plasmid were injected into mice with peritoneal Cancer Gene Therapy, Vol 8, No 11, 2001 disseminated tumor 7 days after injection of tumor cells. HVJ cationic liposomes or HVJ anionic liposomes containing 75 g of pcLuc diluted in 500 l of phosphate -buffered saline (PBS ) were used for each mouse. Twenty-four hours after injection of HVJ cationic liposomes or HVJ anionic liposomes, the mice were killed, and the tumor masses and nontumorous organs including the colon, small intestine, liver, kidney, diaphragm, lung, stomach, spleen, greater omentum, peritoneum, and mesentery were removed and minced in five volumes of passive lysis buffer ( Invitrogen ). All steps were done on ice. After centrifugation at 2380Âg at 48C for 10 minutes, 20 l of the supernatant was tested for luciferase activity. To examine temporal expression of the luciferase gene, the mice were killed 1, 3, 5, and 7 days after the injection of HVJ cationic liposomes, and the tumor masses were removed and examined by luciferase assay.
Introduction of FITC -labeled oligodeoxynucleotides
FITC -labeled oligodeoxyribonucleotides (FITC -ODN ) ( 5
0 -FITC -CCTTGAAGGGATTTCCCTCC -3 0 ) were purchased from Hokkaido System Science CO, Ltd (Sapporo, Japan ). FITC -ODN (1932 g ) in 200 l BSS was mixed with 10 mg dried lipids to prepare HVJ cationic liposomes as described above. HVJ cationic liposomes containing FITC -ODN were injected into colon cancer model mice according to the same method as the luciferase assay. As a negative control, HVJ liposomes containing unlabeled ODN were prepared and introduced into cells and a tumor mass. Twenty-four hours after introduction, tumor masses and normal tissue were fixed with 4% paraformaldehyde. Frozen sections ( 5 m thick ) were observed under a fluorescence microscope after staining the nuclei with Hoechst 33258 (1 g /mL ). To visualize the tumor tissue, the serial section was stained with hematoxylin and eosin.
In vivo transfection of MIP -1
Eight -week -old male BALB /c mice were used for in vivo transfection. Murine colon adenocarcinoma cells ( CT26, 1.5Â10 6 cells in 500 l of PBS ) were injected intraperitoneally. Twenty -four hours after injection of tumor cells, HVJ cationic liposomes containing 50 g pORFmMIP-1, 50 g pORF (control ), or saline were injected into the peritoneal cavity of the mice with peritoneally disseminated tumor. HVJ cationic liposomes were diluted with 500 l of PBS.
Statistical analysis
The Bonferroni /Dunn test was used to determine whether differences were statistically significant. P < .05 was considered significant.
RESULTS
Immunohistochemical evaluation of T -cell migration
We examined immunohistochemistry to evaluate expression of the MIP -1 gene and T-cell migration. As shown in Figure 1a -d, 1 day after injection of HVJ cationic liposomes containing MIP -1 gene, MIP -1 protein was detected in the subcutaneous tumor, whereas control plasmid (pORF ) produced no MIP -1 proteins. As shown in Figure 2a and b, 1 week after injection into the subcutaneous tumor of HVJ cationic liposomes containing the MIP -1 gene CD4 + T lymphocytes were observed around the tumor, whereas no CD4 + T lymphocytes were observed in controls. But, as shown in Figure 2c and d, CD8
+ T lymphocytes were absent around the tumor 1 week after the injection of HVJ cationic liposomes containing MIP -1 gene or pORF (control ). 
Peritoneal disseminated colon tumor model
We examined the peritoneally disseminated colon tumors 2 weeks after intraperitoneal injection of CT26 tumor cells (1.5Â10 6 Figure 3 , we found many disseminated tumors in the intraperitoneal cavity. Metastasis to the lymph nodes around the root of the mesentery was also detected frequently.
cells ). As shown in
In vivo gene transduction for peritoneal disseminated tumors
We used the luciferase gene as a reporter gene to measure expression of the MIP -1 gene. To evaluate tumor specificity of HVJ cationic liposomes in peritoneal cavitydisseminated colon tumor cells, 7 days after intraperitoneal Cancer Gene Therapy, Vol 8, No 11, 2001 injection of CT26 tumor cells ( 1.5Â10 6 cells ) HVJ cationic liposomes or HVJ anionic liposomes containing pcLuc were injected into the peritoneal cavities of mice with peritonealdisseminated tumors. Twenty-four hours after injection of HVJ cationic liposomes or HVJ anionic liposomes, mice were killed, and the tumor masses and other nontumorous organs were removed and examined for luciferase. As shown in Figure 4A , tumor masses treated with HVJ cationic liposomes showed higher luciferase activities than did other organs including the colon, small intestine, liver, kidney, diaphragm, lung, stomach, spleen, greater omentum, peritoneum, and mesentery. In contrast, gene expression in tumor masses treated with HVJ anionic liposomes containing pcLuc was much lower than in those treated with HVJ cationic liposomes, though the liver was transduced similarly by both types of liposomes. To examine temporal expression of the luciferase gene, mice were killed 1, 3, 5, and 7 days after the injection of HVJ cationic liposomes, and the tumor masses were removed and examined by luciferase assay. As shown in Figure 4B , high expression of the luciferase gene was observed 1 day after injection of plasmid. Luciferase gene expression continued until day 7, but the level of expression was low. These findings indicate that HVJ cationic liposomes are effective vectors for gene therapy of peritoneal dissemination of cancer.
The efficiency of FITC -ODN delivery by HVJ cationic liposome system FITC -ODNs were introduced into colon cancer model mice by using the HVJ cationic liposome. Twenty -four hours later, the detection of FITC -ODN was exclusively detected in the tumor area ( Fig 5c, f, and i) . Approximately 40% of tumor nodules received FITC -ODN. In those tumor nodules, FITC -ODN were detected in the nuclei at the efficiency of 94.0%. Furthermore, no fluorescence was detected either in the normal colon tissue (Fig 5l ) or in the tumor mass transfected with HVJ liposomes containing unlabeled ODN ( Fig 5o and r) .
Immunotherapy for peritoneal disseminated colon cancer
The effect of MIP -1 on disseminated colon cancer was examined in a mouse peritoneal disseminated colon tumor model. Murine colon adenocarcinoma cells (CT26, 1.5Â10 6 cells in 500 l of PBS ) were injected intraperitoneally. Twenty -four hours after injection of tumor cells, HVJ Hematoxylin and eosin  staining (b, e, h, k, n, q) , FITC -ODN detection ( c, f, i, l ) and Hoechst 33258 staining (d, g, j, m, p, s) of the consecutive sections of ( A ) ( b, c, d ), ( B ) ( e, f,  g ) and ( C ) ( h, i, j ) are shown. As negative controls, sections of a normal colon tissue with HVJ cationic liposome containing FITC -ODN ( k, l, m ) and a tumor nodule of another mouse transfected with HVJ cationic liposomes containing unlabeld ODN ( n -s ) are used. Original magnifications of sections are Â200 ( h -j, n -p ) and Â400 ( b -g, k -m, q -s ). cationic liposomes containing pORF -mMIP -1 or pORF ( control ) or saline were injected into the peritoneal cavity of the mice. As shown in Figure 6 , the survival periods of mice treated with MIP -1 were significantly longer than those of the control mice ( P= .038 ). Four weeks after injection of tumor cells, all mice treated with saline ( n = 15) were dead, 9 of 11 mice treated with pORF (n = 11 ) were dead, and 7 of 12 mice treated with MIP -1 (n =12 ) were dead. At day 79 after injection of tumor cells, all mice treated with pORF ( n= 11 ) were dead, whereas 10 of 12 mice treated with MIP -1 (n = 12) were dead. Three independent experiments were done. In all the experiments, the anticancer effect of MIP -1 was significant (P < .05).
DISCUSSION
We demonstrated in the present study that MIP -1 delivered by HVJ cationic liposomes significantly increased survival rate of mice peritoneal disseminated colon tumor model. Although immune -based gene therapy has garnered much attention as a promising therapeutic strategy for malignant cancers, the effectiveness has not yet been established. To enhance antitumor immunity, tumor-associated antigens ( TAAs ) have been isolated for some tumors. Based on these TAAs, cancer vaccines have been developed to treat melanomas, which are malignant but immunogenic. For cancers whose TAAs have not yet been identified, researchers have attempted to enhance nonspecific whole body immunity with cytokines including interferon -gamma, IL -2, and IL -12. Transfer of gene -encoding cytokines to specific antigen -presenting cells (APC ), such as dendritic cells (DC ), have been performed extensively. Like ex vivo, improving the efficiency of in vivo tumor recognition by the immune system in tumor-bearing individuals is necessary. Chemokines can induce immunity against inflammation and infection by enhancing the migration of APC and T lymphocytes to such areas. Therefore, chemokines may also enhance the immune response to tumors by accelerating the migration of immune cells to cancerous tissues. In the present study, we investigated involvement of CD4 + T cells in tumor suppression by transferring the MIP -1 gene to the tumor. This strategy served as a successful gene therapy for peritoneally disseminated colon cancer in mice. The observed accumulation of CD4 + T cells around the cancer masses was as expected. Indeed, 1 week after gene transfer, CD4 + lymphocytes were visible around the tumor mass, whereas CD8 + lymphocytes were not present. MIP -1 expression was still detectable by day 7 after transfer. Therefore, expression of MIP -1 may be sufficient to induce migration of CD4 + but not CD8 + lymphocytes. Forty -two percent of mice with peritoneal dissemination of CT26 cells were alive on day 28 after tumor inoculation whereas all of the saline -injected control mice had died. -Chemokines (MIP-1, MIP-1, and RANTES ) may be Th1 polarizing or associated with Th1 -polarized immunity in some immunity. 24 -30 MIP -1, MIP-1, and RANTES may be efficient chemoattractants for Th1 cells, 31 with MIP -1 acting mostly on CD4 + T cells. 32 The CC chemokine receptor 5 (CCR5 ) is highly expressed on Th1. 33, 34 As MIP - 35, 36 and secrete -chemokines. 37, 38 Furthermore, it is possible that an unidentified MIP -1 receptor might mediate some of these effects. More clarification of the role of MIP -1 in vivo requires further investigations. In conclusion, we demonstrated that CD4 + helper T cells attracted around the site of tumor directly or indirectly by MIP -1 show antitumor effect. Therefore, migration of CD4 + lymphocytes into cancers appears to be necessary to enhance the antitumor therapeutic effect. However, it is possible that a combination of other cytokines and MIP -1 may further increase antitumor immunity. In a preliminary study, we observed that cotransfer of secondary lymphoid tissue chemokine ( SLC ) with MIP -1 increased the survival of tumorbearing mice more than did the transfer of each chemokine alone (Miyata, unpublished data ) .
Interestingly, in comparison to HVJ cationic liposomes containing saline, injection of control plasmid pORF prolonged survival of tumor-harboring mice ( P <.05 ). In the subcutaneous tumor model, CD4 + T cells were not observed by pORF. We speculate that the CpG island contained in the plasmid DNA might function as an immunostimulatory sequence ( ISS) and induce production of interferon or activation of NK cells. 39 In the present experiments, we chose HVJ cationic liposomes as the gene delivery system, because this system could preferentially transfer the gene of interest to cancer masses in the peritoneal cavity. In an experiment with green fluorescent protein (GFP ), we showed that HVJ cationic liposomes are an effective delivery system for gene therapy with the VEGF receptor ( soluble form ) after peritoneal dissemination of gastric cancers. 40 However, HVJ cationic liposomes are much less efficient than HVJ anionic liposomes for gene transfer to solid organs such as the liver muscle and kidney. Although the reason for this difference is unclear, we suspect that cancerous tissue may differ from normal solid tissues with respect to characteristics such as adhesion, density, and surface charge. One advantage of HVJ liposomes is the possibility for gene transfer because of the low immunogenicity. 41 Repeated injection of chemokine genes may further increase the survival of tumor-bearing mice. Moreover, if an Epstein -Barr virus ( EBV ) -replicon vector system is used for the expression of MIP -1, expression of the transgene may be sustained for a longer period. We have already observed long -term gene expres-sion using an EBV -replicon vector system in conjunction with HVJ liposomes in liver, 42 muscle, 43 kidney, 44 and cancer masses (Otomo et al, unpublished data ).
The present study indicates that MIP -1, like other chemokines, may be a promising factor for gene therapybased cancer treatments.
